Serum TAU Is Predictive Of 6-month Cognitive Outcome Following Cardiac Arrest
Posted on
PDF2011 NEUROSCIENCE, WASHINGTON, DC
J.D. Randall,1 H. Zetterberg,3 E. Mortberg,2 S. Rubertsson,2 G. Provuncher,1 P. Patel,1 E. Ferrell,1 D. Fournier,1 C. Kan,1 T. Campbell,1 A. Rivnak,1 B. Pink,1 K. Minnehan,1 T. Piech,1 D. Duffy,1K. Blennow,3D. Wilson1
1Quanterix Corporation, Cambridge, MA; 2Department of Surgical Sciences, Anaesthesia and Intensive Care, Uppsala University, Uppsala, Sweden; 3Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at the University of Gothenburg, Molndal, Sweden.
Background: Tau, a microtubule associated protein, plays an important role in the assembly of tubulin monomers into microtubules and maintaining the cytoskeleton and axonal transport. The presence of tau in cerebrospinal fluid (CSF), serum or plasma is thought to represent neuronal damage from physical trauma or apoptotic death of neurons. During ischemic injury from cardiac arrest, cell death could occur from the initial hypoxic insult as well as an apoptotic cascade resulting in delayed neuronal death. The measurement of tau in CSF has been well documented, but the presence and measurement of tau in human blood components has been difficult due to inadequate sensitivity of current assay methods. A direct link between acute oxygen deprivation and the appearance of tau in human periphery has not been previously studied. We employed a new technology (Single Molecule Arrays, SiMoA) capable of ultrasensitive protein measurements to look for changes in serum tau in patients following cardiac arrest and resuscitation, and to correlate these changes to 6-month cognitive outcome.
Share This Post
Related Posts
Next-Generation PhenoCode Molecular Barcoding Chemistry: Enhanced Reliability and Reproducibility for High-Plex Spatial Profiling
Poster Background Reliable and reproducible antibody barcoding is critical for spatial biology workflows onthe Akoya PhenoCycler®-Fusion 2.0 (PCF). We evaluated and optimized a complementarychemistry to the existing Antibody Conjugation Kit…
Neurology
Comparative Spatial Analyses of the Tumor Immune Landscape in Mouse Models of Glioblastoma Using the PhenoCode Discovery Mouse Neuro Panel and Customized Markers
Poster Background Developing effective therapies for glioblastoma (GBM) relies on robust preclinical animal models that enable detailed investigation of tumor biology, discovery of therapeutic targets, and evaluation of new treatment…
Oncology
Development of a Spatial Metabolic Map of Immunotherapy Sensitive and Resistant Cutaneous Skin Carcinoma
Poster Background Ultrahigh-Plex Single-cell Spatial Phenotyping has revealed valuable insights into the tumor immune microenvironment (TiME) for biomarker discovery and stratification of clinical responses. Metabolic reprogramming is a key hallmark…
Spatial Immunometabolic Profiling of Non-Small Cell Lung Cancer Reveals Distinct Immune Exclusion Patterns and Functional Niches
Analytical validation of a multiplex immunofluorescence 7-Biomarker Immunoprint® assay on the Akoya PhenoImager HT platform for stage I/II Melanoma
Neurology
Neurodegenerative biomarkers in different chambers of the eye relative to plasma: an agreement validation study
Alzheimer’s Research and Therapy | August 26, 2024 Sampani K, Ness S, Tuz-Zahra F, Aytan N, Spurlock EE, Alluri S, Chen X, Siegel NH, Alosco ML, Xia W, Tripodis Y,…
Neurology
Clinical validation of the LucentAD p-Tau 217 as a lab developed test (LDT) for clinical use
Poster The intersection of new therapeutic options for Alzheimer’s disease (AD), the emergence of accurate blood-based tests for AD, and the anticipated health system log jam for confirmatory diagnostic testing…
Neurology
Development of thresholds and a visualization tool for use of a blood test in routine clinical dementia practice
Alzheimer’s & Dementia | August 3, 2024 Verberk IMW, Jutte J, Kingma MY, Vigneswaran S, Gouda MMTEE, van Engelen MP, Alcolea D, Arranz J, Fortea J, Lleó A, Chevalier C,…